{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:00:19Z","timestamp":1792461619168,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.virusres.2020.198114","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T21:30:51Z","timestamp":1597267851000},"page":"198114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":674,"special_numbering":"C","title":["COVID-19 Vaccine: A comprehensive status report"],"prefix":"10.1016","volume":"288","author":[{"given":"Simran Preet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14, April","key":"10.1016\/j.virusres.2020.198114_bib0005","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.virusres.2020.198114_bib0010","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two covid\u201019 patients with acute respiratory distress syndrome in Korea","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci."},{"key":"10.1016\/j.virusres.2020.198114_bib0015","series-title":"Countries where COVID-19 has spread","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0020","series-title":"Coronavirus Resource Center","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0025","series-title":"COVID-19 Treatment and Vaccine Tracker","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0030","series-title":"A randomized, double-blind, placebo parallel-controlled phase I\/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) Registration no.: ChiCTR2000031809","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0035","series-title":"UW\u2013Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0040","series-title":"A Study of a Candidate COVID-19 Vaccine (COV001)","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0045","series-title":"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0050","series-title":"Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0055","series-title":"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0060","series-title":"HKU joins global partnership to develop COVID-19 vaccine","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0065","series-title":"(BAT), British and American Tobacco Company. Potential COVID-19 vaccine \u2013 BAT in the news","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0070","series-title":"Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0075","series-title":"Safety and Immunity of Covid-19 aAPC Vaccine","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0080","series-title":"Sinovac gets regulatory approval to assess Covid-19 vaccine.","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0085","series-title":"Sinovac reports positive data from Phase I\/II trials of CoronaVac.","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0090","series-title":"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug \"Gam-COVID-Vac\" Vaccine Against COVID-19","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0095","series-title":"An Open Study of the Safety, Tolerability and Immunogenicity of \"Gam-COVID-Vac Lyo\" Vaccine Against COVID-19","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0100","series-title":"Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0105","series-title":"Zydus Cadila looks to expedite Covid-19 vaccine development","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0110","series-title":"Draft landscape of COVID-19 candidate vaccines","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0115","series-title":"Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0120","series-title":"A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0125","series-title":"BIOCAD started working on mRNA vaccine against coronavirus","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0130","series-title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With\/Without Matrix-M Adjuvant","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0135","series-title":"Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0140","series-title":"COVID-19 Vaccine Development Program","author":"Anon","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0145","series-title":"A randomized, double-blind, placebo parallel-controlled phase I\/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0150","series-title":"Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial","author":"Anon","year":"2020"},{"issue":"March","key":"10.1016\/j.virusres.2020.198114_bib0155","article-title":"Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection","author":"Anon","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.virusres.2020.198114_bib0160","series-title":"COVID-19 \/ SARS-CoV-2","author":"Anon","year":"2020"},{"issue":"May 19","key":"10.1016\/j.virusres.2020.198114_bib0165","article-title":"Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate. Gurugram : s.n","author":"Arora","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.virusres.2020.198114_bib0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jmv.25698","article-title":"Immunoinformatics\u2010aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019\u2010nCoV","author":"Baruah","year":"2020","journal-title":"J Med Virol."},{"key":"10.1016\/j.virusres.2020.198114_bib0175","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","author":"Breedveld","year":"2000","journal-title":"The Lancet"},{"key":"10.1016\/j.virusres.2020.198114_bib0180","series-title":"Applied DNA Sciences Subsidiary, LineaRx, and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV","author":"BROOK, STONY","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0185","series-title":"Current Efforts in COVID-19 Vaccine Development","author":"Campbell","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06151-y","article-title":"Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant","author":"Cao","year":"2018","journal-title":"Nat Commun."},{"key":"10.1016\/j.virusres.2020.198114_bib0195","series-title":"Virology: Principles and Applications","first-page":"382","author":"Carter","year":"2007"},{"key":"10.1016\/j.virusres.2020.198114_bib0200","series-title":"How COVID-19 Spreads","author":"(CDC), Centers for Disease Control and Prevention","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0205","article-title":"Coronavirus Disease 2019 (COVID-19)- Symptoms of Covid-19","author":"CDC","year":"2020","journal-title":"Centres for Disease Control and Prevention"},{"key":"10.1016\/j.virusres.2020.198114_bib0210","first-page":"3169","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","author":"Coleman","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2020.198114_bib0215","series-title":"NCBI","author":"Conserved Protein Domain Family: SARS-like-CoV_M","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0220","series-title":"Around 30 Indian attempts at COVID-19 vaccine, says Principal Scientific Adviser.","author":"Coronavirus","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0225","unstructured":"CTRI\/2020\/07\/026352. 2020 http:\/\/ctri.nic.in\/. [Online] July 31, 2020. [Cited: August 01, 2020.] http:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=45306&EncHid=&userName=Zydus."},{"key":"10.1016\/j.virusres.2020.198114_bib0230","first-page":"594","article-title":"Advances in mRNA Vaccines for Infectious Diseases","author":"Cuiling","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.virusres.2020.198114_bib0235","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25858","article-title":"Role of Nonstructural Proteins in the Pathogenesis of SARS-CoV-2","author":"da Silva","year":"2020","journal-title":"Journal of medical virology"},{"key":"10.1016\/j.virusres.2020.198114_bib0240","article-title":"Complexity of the Basic Reproduction Number (R0)","volume":"25","author":"Delamater","year":"2019","journal-title":"s.l. : Emerging Infectious Diseases"},{"key":"10.1016\/j.virusres.2020.198114_bib0245","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2020.1735227","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","author":"Dhama","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.virusres.2020.198114_bib0250","article-title":"Jonathan ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"Doremalen","year":"2020","journal-title":"s.l. : bioRxiv"},{"key":"10.1016\/j.virusres.2020.198114_bib0255","article-title":"Emergence of genomic diversity and recurrent mutations in SARS-CoV-2","volume":"104351","author":"Dorp","year":"2020","journal-title":"s.l. : Infection, Genetics and Evolution"},{"key":"10.1016\/j.virusres.2020.198114_bib0260","first-page":"1752","article-title":"Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure","author":"Eyal","year":"2020","journal-title":"s.l. : The Journal of infectious diseases"},{"issue":"July","key":"10.1016\/j.virusres.2020.198114_bib0265","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.virusres.2020.198114_bib0270","article-title":"An Integrated In-Silico Approach to Develop Epitope-Based Peptide Vaccine against SARS-CoV-2","author":"Garg","year":"2020","journal-title":"s.l. : Preprints"},{"key":"10.1016\/j.virusres.2020.198114_bib0275","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0165-6147(99)01382-6","article-title":"Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery","author":"Gelboin","year":"1999","journal-title":"Trends in Pharmacological Sciences."},{"key":"10.1016\/j.virusres.2020.198114_bib0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the Coronavirus: 2019-nCoV","author":"Gralinski","year":"2020","journal-title":"Viruses"},{"issue":"May 29","key":"10.1016\/j.virusres.2020.198114_bib0285","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","author":"Graham","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.virusres.2020.198114_bib0290","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2005.11.042","article-title":"SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens","volume":"347","author":"Gupta","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2020.198114_bib0295","series-title":"Heat Biologics","author":"Heat Biologics\u2019 COVID-19 Vaccine Program","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0300","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.3390\/ijms19113605","article-title":"DNA Vaccines-How Far From Clinical Use?","author":"Hobernik","year":"2018","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.virusres.2020.198114_bib0305","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"May","key":"10.1016\/j.virusres.2020.198114_bib0310","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","author":"Imai","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"July","key":"10.1016\/j.virusres.2020.198114_bib0315","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report","author":"Jackson","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.virusres.2020.198114_bib0320","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies","author":"Jiang","year":"2020","journal-title":"Emerging microbes & infections"},{"key":"10.1016\/j.virusres.2020.198114_bib0325","series-title":"Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use","author":"Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19","year":"2020"},{"issue":"April","key":"10.1016\/j.virusres.2020.198114_bib0330","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Kai","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.virusres.2020.198114_bib0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virusres.2020.198114_bib0340","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application","author":"Lauer","year":"2020","journal-title":"Ann Intern Med."},{"issue":"5","key":"10.1016\/j.virusres.2020.198114_bib0345","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.virusres.2020.198114_bib0350","article-title":"These 23 companies are working on coronavirus treatments or vaccines \u2014 here\u2019s where things stand","author":"Lee","year":"2020","journal-title":"Market watch"},{"key":"10.1016\/j.virusres.2020.198114_bib0355","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases","author":"Liu","year":"2020","journal-title":"ACS Central Science"},{"key":"10.1016\/j.virusres.2020.198114_bib0360","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/14712598.1.4.641","article-title":"Fighting infection using immunomodulatory agents","author":"Masihi","year":"2001","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.virusres.2020.198114_bib0365","article-title":"The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic","author":"Mice","year":"2020","journal-title":"s.l. : bioRxiv"},{"key":"10.1016\/j.virusres.2020.198114_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","author":"Michot","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.virusres.2020.198114_bib0375","article-title":"Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report; preprint","author":"Mulligan","year":"2020","journal-title":"s.l. : medRxiv"},{"key":"10.1016\/j.virusres.2020.198114_bib0380","series-title":"Race for COVID-19 vaccine: Covaxin and ZyCoV-D begin human trials in India, Moderna publishes preliminary data from phase 1","author":"Myupchar","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0385","series-title":"Top Indian scientists join global fight against coronavirus","author":"Nandi","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0390","article-title":"Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses","author":"Ning","year":"2020","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.virusres.2020.198114_bib0395","series-title":"Clinical Trials Arena","author":"Novavax covid 19 vaccine trial","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0400","first-page":"11","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"1620","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.virusres.2020.198114_bib0405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3345\/cep.2020.00493","article-title":"Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)","author":"Park","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.virusres.2020.198114_bib0410","series-title":"Chernyshev, Anatoly","author":"Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0415","series-title":"DBT\/ Anti-COVID consortium- Efforts underway to produce therapeutic antibodies against COVID-19: Isolating genes encoding antibodies for neutralising the SARS-CoV-2, COVID-19","author":"PIB, Delhi","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0420","first-page":"565","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","author":"Prof Roujian","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.virusres.2020.198114_bib0425","series-title":"100 Years after the Spanish Flu: Lessons Learned and Challenges for the Future","author":"Pyrek","year":"2018"},{"key":"10.1016\/j.virusres.2020.198114_bib0430","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0170-0","article-title":"The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines","author":"Shang","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"16","key":"10.1016\/j.virusres.2020.198114_bib0435","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.virusres.2020.198114_bib0440","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.virusres.2020.198114_bib0445","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19. 2601","volume":"11","author":"Smith","year":"2020","journal-title":"s.l. : Nat Commun"},{"key":"10.1016\/j.virusres.2020.198114_bib0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.virusres.2020.198114_bib0455","series-title":"Online] Tonix Pharmaceuticals","author":"TNX-1800 (Coronavirus Vaccine)","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0460","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.virusres.2020.198114_bib0465","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A Review of SARS-CoV-2 and the Ongoing Clinical Trials","author":"Tu","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.virusres.2020.198114_bib0470","series-title":"Italy claims to have developed the first COVID-19 vaccine: Here is what we know about all the potential coronavirus vaccines.","author":"Upadhyay","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0475","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virusres.2020.198114_bib0480","series-title":"Enters into Sponsored Research Agreement with The Vaccine & Immunotherapy Center at the Massachusetts General Hospital to Develop Potential COVID-19 Vaccine","author":"Voltron Therapeutics, Inc","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0485","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virusres.2020.198114_bib0490","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virusres.2020.198114_bib0495","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS","author":"Wan","year":"2020","journal-title":"J Virol."},{"key":"10.1016\/j.virusres.2020.198114_bib0500","series-title":"Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease","author":"(WHO), World Health Organisation","year":"2014"},{"key":"10.1016\/j.virusres.2020.198114_bib0505","series-title":"Coronavirus disease (Covid-19) Situation Report- 164","author":"(WHO) World Health Organisation","year":"2020"},{"key":"10.1016\/j.virusres.2020.198114_bib0510","series-title":"Draft landscape of COVID-19 candidate vaccines","author":"WHO","year":"2020"},{"issue":"13 March","key":"10.1016\/j.virusres.2020.198114_bib0515","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Mclellan Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virusres.2020.198114_bib0520","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Commentary genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virusres.2020.198114_bib0525","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.virusres.2020.198114_bib0530","unstructured":"Yan, Xuebing. 2020 http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49544. http:\/\/www.chictr.org.cn. [Online] February 2020."},{"key":"10.1016\/j.virusres.2020.198114_bib0535","first-page":"25","article-title":"Hong Kong Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS: s.n","author":"Yip","year":"2016","journal-title":"Hong Kong medical journal = Xianggang yi xue za zhi \/ Hong Kong Academy of Medicine"},{"key":"10.1016\/j.virusres.2020.198114_bib0540","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10930-020-09901-4","article-title":"The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19","author":"Yoshimoto","year":"2020","journal-title":"The protein journal"},{"key":"10.1016\/j.virusres.2020.198114_bib0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","author":"Zhai","year":"2020","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.virusres.2020.198114_bib0550","first-page":"30571","article-title":"Treatment with convalescent plasma for critically ill patients with SARS\u2010CoV\u20102 infection","volume":"2020","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.virusres.2020.198114_bib0555","article-title":"Safety, tolerability, and immunogenicity of a recombinan tadenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"issue":"July","key":"10.1016\/j.virusres.2020.198114_bib0560","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Zhu","year":"2020","journal-title":"The Lancet"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220310212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220310212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:10:33Z","timestamp":1759155033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170220310212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":112,"alternative-id":["S0168170220310212"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198114","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 Vaccine: A comprehensive status report","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"198114"}}